Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...

Strategic investments in development-stage candidates with potential for high returns. Market competition and regulatory changes pose significant ... Royalty Pharma PLC (NASDAQ:RPRX), the industry ...

This approach supports our long-term objective of establishing Bionoid Pharma as a leader in AI-powered health solutions." The AI-driven platform at the heart of BINP's growth strategy will ...

Anti-abortion groups plan to unveil a sprawling federal and state strategy today that would undermine the procedure’s protections enacted by ballot measure in nearly a dozen states over the past two ...

As you know, maintaining compliance with industry standards is crucial for ensuring the safety and quality of sterile medicinal ...

In order to enhance share liquidity and expand the number of investors trading in the companys shares, Sudarshan Pharma ...

Teva Pharmaceutical Industries Ltd (TEVA ... optimizing its operational footprint, and executing on strategic portfolio changes. For additional insights on Teva’s stock performance and ETF ...

Cipla’s FDA-compliant facilities and its investments in US-based units place it in a strong position to weather potential ...

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to ... Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd ...

To date, we have successfully renewed every single large pharma strategic partnership ... There is no material change from our prior guidance to our assumptions around COVID related step-down ...

These changes reflect a new dual CEO-COO leadership structure to help support the business’ continued growth. Miyamoto, as Chairman and CEO, will lead discussions on Kyowa Kirin's direction and ...